2,4-disubstituted pyrimidines useful as kinase inhibitors

A compound of formula I-b:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• Ring B is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R1 is a warhead group -L-Y, or R1 is selected from:
• wherein R1 is attached to Ring A at a position other than an atom adjacent to the atom attached to W1;
• L is —NRC(O)CH═CH—, —NRC(O)CH═CHCH2N(CH3)—, —NRC(O)CH═CHCH2O—, —NRSO2CH═CH—, —NRSO2CH═CHCH2—, —NRC(O)(C═N2)—, —NRC(O)(C═N2)C(O)—, —NRC(O)C(═CH2)CH2—, —CH2NRC(O)—, —CH2NRC(O)CH═CH—, —CH2CH2NRC(O)—, —CH2NRC(O)cyclopropylene-, —C(O)CH═C(CH3)—, —C(O)CH═CHCH2NH(CH3)—, —C(O)CH═CH—, —CH2C(O)CH═CH—, —CH2C(O)CH═C(CH3)—, —CH2CH2C(O)CH═CH—, —CH2CH2C(O)CH═CHCH2—, —CH2CH2C(O)CH═CHCH2N(CH3)—, —CH2CH2C(O)CH═C(CH3)—, —CH(CH3)OC(O)CH═CH—, —CH2OC(O)CH═CHCH2—, —CH2OC(O)CH═CH— or —CH(CH═CH2)OC(O)CH═CH—;
• wherein R is H or optionally substituted C1-6 aliphatic;
• and Y is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN;
• Ry is hydrogen, halogen, —CN, —CF3, C1-4 aliphatic, C1-4 haloaliphatic, —OR, —C(O)R, or —C(O)N(R)2;
• each R group is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• W1 is —O—;
• W2 is —NR2—;
• R2 is hydrogen, optionally substituted C1-6 aliphatic, or —C(O)R;
• m and p are independently 0, 1, 2, 3 or 4;
• and
• Rx is selected from —R, halogen, —OR, —O(CH2)qOR, —NO2, —SO2R, —SO2N(R)2, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2, wherein q is 1, 2, 3 or 4;
• Rv is selected from —R, halogen, —OR, —O(CH2)qOR, —CN, —NO2, —SO2R, —SO2N(R)2, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2, wherein q is 1, 2, 3 or 4;
• or:
• Rv and R1 when concurrently present on Ring A are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with a warhead group and 0-3 groups independently selected from oxo, halogen, CN, or C1-6 aliphatic.